乙双吗啉(AT1727,简称AT)是我国合成的抗肿瘤药物,虽然对它是否为放射增敏剂还未作定论,但体内、外实验的结果显示了它作为放射增敏剂的希望,而且在和放射合用后肯定提高了联合治疗的抗肿瘤效应。张志义报道治疗原发性肺癌的临床试验初步结果也发现该药有放射增效作用。所以,我们对鼻咽癌作了如下临床第Ⅲ期随机对照试验,以进一步研究AT在人类肿瘤中是否有放射增效作用以及临床实用价值。 Ethyl bismorpholine (AT1727, abbreviated as AT) is an anti-tumor drug synthesized in China. Although no conclusion has been made as to whether it is a radiosensitizer, the results of in vitro and in vivo experiments have shown its promise as a radiosensitizer. And after combined with radiation, it definitely increases the anti-tumor effect of combination therapy. Zhang Zhiyi reported that preliminary results of clinical trials for the treatment of primary lung cancer also found that the drug had a radiosensitizing effect. Therefore, we conducted the following clinical phase III randomized controlled trials on nasopharyngeal carcinoma to further investigate whether AT has radiosensitivity and clinical utility in human tumors.